# TrasGEX™: Phase 1 Study in Cancer Patients

> **NCT01409343** · PHASE1 · COMPLETED · sponsor: **Glycotope GmbH** · enrollment: 37 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** TrasGEX™

## Key facts

- **NCT ID:** NCT01409343
- **Lead sponsor:** Glycotope GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07
- **Primary completion:** 2013-11
- **Final completion:** 2013-12
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2021-05-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01409343

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01409343, "TrasGEX™: Phase 1 Study in Cancer Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01409343. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*